Trial Profile

A phase 2 study of EB612 for the treatment of hypoparathyroidism

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 14 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teriparatide (Primary)
Indications Postmenopausal osteoporosis
Focus Therapeutic Use

Most Recent Events

09 Aug 2024 According to an Entera Bio media release, company showed that the data from Phase 1 study presented at ENDO 2024 supports potentially moving the BID (twice-daily) tablet dose to Phase 2 development in patients with hypoparathyroidism.
05 Apr 2023 New trial record
03 Apr 2023 According to an Entera Bio media release, the company plans to start this study in 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com